One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.

ABSTRACT: OBJECTIVE:To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. METHODS:Patients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or erenumab 70 or 140 mg. At week 24, 845 patients were rerandomized (1:1) to erenumab 70 or 140 mg during the 28-week dose-blinded active-treatment phase (ATP). Monthly migraine days (MMD), achieving ≥50%, ≥75%, and 100% reduction in MMD, and safety/tolerability were assessed. RESULTS:Mean MMD at DBTP baseline was 8.3. At week 52, mean changes (SE) from pre-DBTP baseline/week 24 (pre-ATP baseline) in MMD were -4.2 (0.2)/-1.1 (0.2) (70 mg) and -4.6 (0.2)/-1.8 (0.2) (140 mg) irrespective of treatment during the DBTP. For patients reducing dose fro

SUBMITTER: Goadsby PJ 

PROVIDER: S-EPMC7455346 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature